Key facts
- This page summarizes Alan R. Stewart's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jan 2025, 17:27.
Alan R. Stewart - 31 Dec 2024 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)
- Reporting relationship
- Director
- Issuer ticker
- CLDI
- Reported as of
- 31 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2025, 17:27:37 UTC
- Prior SEC filing
- 12 Dec 2024
- Next SEC filing
- 04 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Jackson, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alan R. Stewart filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 03 Jan 2025.
Change
- Previous filing in this sequence was filed on 12 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLDI
transaction
Common Stock
Award
- Transaction value
- Shares
- +12,771
- Change %
- +79%
- Price
- Shares after
- 28,976
- Date
- 31 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents a grant of restricted stock units ("RSUs") on December 31, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with a payment in lieu of cash for services during the Issuer's fourth fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date. The price per share at which the grants were issued is $1.15 and was determined based on the Issuer's closing price on December 31, 2024.
SEC remarks
Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 4 dated July 2, 2024.)